EBS News and Press, Emergent Biosolutions Inc. From 07/25/22

The European Commission (EC) approved the expanded use of Bavarian Nordic's ( OTCPK:BVNKF ) ( OTCPK:BVNRY ) smallpox vaccine Imvanex for use in preventing monkeypox and disease caused by vaccinia virus. The Denmark-based company's stock rose +4.73% to DKK349.8 o...

The World Health Organization (WHO) designated the current monkeypox outbreak a public health emergency of international concern (PHEIC) on Saturday. PHEIC designation is WHO's highest level of warning, previously issued for the COVID-19 pandemic and Ebola. The decision follows a ...

A committee of the European Medicines Agency ( EMA ) recommended the expanded approval of Bavarian Nordic's ( OTCPK:BVNKF ) ( OTCPK:BVNRY ) smallpox vaccine Imvanex for use in preventing monkeypox. The Denmark-based company's smallpox vaccine MVA-BN is sold as Jynneo...

GAITHERSBURG, Md., July 18, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Monday, August 1, 2022, at 5:00 pm eastern time to discuss the financial results for the second quarter of 2022, recent business developments, revenue guidance for the ...

Johnson & Johnson ( NYSE: JNJ ) is scheduled to announce Q2 earnings results on Monday, July 18th, before market open. EPS Estimate is $2.55 (+2.8% Y/Y) and the consensus Revenue Estimate is $23.86B (+2.4% Y/Y). has beaten EPS estimates 100% of the time and has bea...

Companies focused on monkeypox vaccines and therapeutics gained in the pre-market Monday after the Danish biotech Bavarian Nordic ( OTCPK:BVNKF ) ( OTCPK:BVNRY ) ( BAVN ) increased its 2022 financial guidance to reflect the recent supply contracts for its monkeypox vaccine, ...

United Kingdom has approved SIGA Technologies's ( NASDAQ: SIGA ) oral tecovirimat for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox in adults and children with a body weight of at least 13kg. Similar formula...

Emergent BioSolutions ( NYSE: EBS ) on Thursday said it had entered into a collaboration agreement with Ridgeback Biotherapeutics for its FDA-approved ebola treatment Ebanga. Ridgeback's Ebanga, a monoclonal antibody, was approved by the U.S. drug regulator in Dec. 202...

GAITHERSBURG, Md. and MIAMI, July 07, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has entered into an agreement with Ridgeback Biotherapeutics (“Ridgeback Bio”), a biotechnology company focused on emerging infectious diseases, intend...

The World Health Organization (WHO) is set to reconvene a meeting of its advisors this month to decide whether the monkeypox constitutes a global health emergency after reporting more than 8,000 cases from 58 countries in the current outbreak. "I continue to be concerned by the scal...